Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

CellMax Life receives six U.S. patents for early cancer detection blood test

CellMax Life, enabling early cancer detection and management with affordable, non-invasive blood tests, announced today that six U.S. patents have been granted for its biomimetic platform CMx, which detects circulating tumor cells.

26 Jul 2018

Omeros’ OMS721 receives positive opinion from EMA's COMP for treating hematopoietic stem cell transplant

Omeros Corporation announced today that the European Medicines Agency's Committee for Orphan Medicinal Products issued a positive opinion recommending orphan drug designation of OMS721 for treatment in hematopoietic stem cell transplantation.

25 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints

Pfizer Inc. and Eli Lilly and Company today announced that a 16-week Phase 3 study in patients with osteoarthritis pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints.

19 Jul 2018

New clinical trial to evaluate virotherapy and immunotherapy combination for ovarian, colorectal cancers

Ludwig Cancer Research and the Cancer Research Institute announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI (durvalumab) for advanced ovarian and colorectal cancers.

12 Jul 2018

Ludwig-developed antibody drug for deadly brain cancer may have broader applications

A Ludwig Cancer Research study explains why a particular mutation in the epidermal growth factor receptor, a cell surface protein, results in more aggressive tumors and poorer overall survival of patients diagnosed with the brain cancer glioblastoma multiforme.

10 Jul 2018

Atlantic Health System starts enrolling patients in four pancreatic cancer clinical trials

Atlantic Health System is now enrolling patients in four pancreatic cancer clinical trials. Angela Alistar, MD, a nationally known expert on pancreatic cancer, is serving as national Principal Investigator on the first trial and as local PI on three other trials.

30 Jun 2018

Study reveals new way to inhibit capillary leakage in sepsis

Leakage from the blood capillaries is a key mechanism leading to septic shock and multiorgan failure, which affect millions of patients annually worldwide. However, there is no effective way to inhibit the vessel leakiness. A new study by scientists at the University of Helsinki and Wihuri Research Institute demonstrates that vascular leakage can be inhibited by targeting vascular integrins.

25 Jun 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Study finds increased risk of mortality in people with cold agglutinin disease in five years after diagnosis

Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, today announced results from a new, population-based retrospective study that found a greater than twofold increased risk of mortality in people with cold agglutinin disease within the first five years after diagnosis.

18 Jun 2018

Innovative drugs and new European treatment guidelines refine, improve MS therapy

MS is the most common neurological disease in young adults. There are about 2.3 million people worldwide who face a high risk of ever worsening disabilities from this disease.

18 Jun 2018

Canakinumab reduces gout rate by more than half in atherosclerosis patients, study shows

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half compared to placebo, regardless of baseline serum urate level.

18 Jun 2018

Regeneron collaborates with Zoetis to research antibody therapies for animals

Regeneron Pharmaceuticals, Inc. and Zoetis Inc. today announced a five-year collaboration to research the use of Regeneron's monoclonal antibody therapeutics in animals and discover new veterinary treatments.

6 Jun 2018

Phase I trial shows safety of investigational drug in treating chronic lymphocytic leukemia

Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the "stemness" of chronic leukemia cancer cells - their ability to self-renew and resist terminal differentiation and senescence.

1 Jun 2018

OSU biologist describes 'restoration ecology' approach toward patient health

Chronic diseases like cancer, autoimmune disorders and obesity may ultimately vanquish the efforts of medical intervention unless people change their diet, an Oregon State University biologist argues in a paper published this week.

26 May 2018

Researchers reveal potent new mechanism of action for treatment of IBD

Professor Akiyoshi Fukamizu's research group of Life Science Center for Survival Dynamics, University of Tsukuba, Eisai Co., Ltd. and its gastrointestinal business subsidiary EA Pharma Co., Ltd. have revealed a mechanism in which an analogue (ER-464195-01) of Eisai's in-house discovered E6007 inhibits integrin activation by dissociating interaction between calreticulin (CRT) and integrin α 4 (ITGA4), suppressing adhesion and infiltration of leukocytes overall.

25 May 2018

NIH commences first-in-human trial evaluating experimental treatment for Ebola

A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland.

24 May 2018

Comparative Analysis of a Complex Monoclonal Antibody

Postnova Analytics has published a new poster that compares the suitability of Electrical Asymmetrical Flow Field Flow Fractionation (EAF4) and Size Exclusion Chromatography (SEC) for determining the physicochemical and biophysical attributes of monoclonal antibodies.

From Postnova Analytics 23 May 2018

UAB-led clinical trial intends to find innovative treatment for multiple myeloma patients

Multiple myeloma is the second most common type of blood cancer in the United States, impacting more than 25,000 people each year and disproportionatly affecting African-American men.

15 May 2018

Monoclonal Antibody News and Research

Further Reading

CNDA approves KEYTRUDA for treatment of advanced melanoma

CellMax Life receives six U.S. patents for early cancer detection blood test

Omeros’ OMS721 receives positive opinion from EMA's COMP for treating hematopoietic stem cell transplant

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints

New clinical trial to evaluate virotherapy and immunotherapy combination for ovarian, colorectal cancers

Ludwig-developed antibody drug for deadly brain cancer may have broader applications

Atlantic Health System starts enrolling patients in four pancreatic cancer clinical trials

Study reveals new way to inhibit capillary leakage in sepsis

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Study finds increased risk of mortality in people with cold agglutinin disease in five years after diagnosis

Innovative drugs and new European treatment guidelines refine, improve MS therapy

Canakinumab reduces gout rate by more than half in atherosclerosis patients, study shows

Regeneron collaborates with Zoetis to research antibody therapies for animals

Phase I trial shows safety of investigational drug in treating chronic lymphocytic leukemia

OSU biologist describes 'restoration ecology' approach toward patient health

Researchers reveal potent new mechanism of action for treatment of IBD

NIH commences first-in-human trial evaluating experimental treatment for Ebola

Comparative Analysis of a Complex Monoclonal Antibody

UAB-led clinical trial intends to find innovative treatment for multiple myeloma patients

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®